TY - JOUR
T1 - Drug Therapy for Graves' Disease during Pregnancy
AU - Rosen, Harold
AU - Gardner, David F.
AU - Cooper, David S.
AU - Momotani, Naoko
AU - Noh, Jaeduk
AU - Oyanagi, Hiroshi
AU - Ishikawa, Naofumi
AU - Ito, Kunihiko
PY - 1986/12/4
Y1 - 1986/12/4
N2 - To the Editor: I greatly enjoyed reading the article by Momotani et al. (July 3 issue)* regarding antithyroid therapy for Graves' disease during pregnancy. There is, however, one comment that needs to be made. In their study, Momotani et al. found no difference between the group of women with hyperthyroidism treated with propylthiouracil and the group of women with hyperthyroidism treated with methimazole, in the proportion of fetuses with suppressed thyroid function. This was contrary to the investigators' expectations, since, “because of its reported limited placental transfer, propylthiouracil is widely preferred over methimazole.” One might be tempted to conclude that.
AB - To the Editor: I greatly enjoyed reading the article by Momotani et al. (July 3 issue)* regarding antithyroid therapy for Graves' disease during pregnancy. There is, however, one comment that needs to be made. In their study, Momotani et al. found no difference between the group of women with hyperthyroidism treated with propylthiouracil and the group of women with hyperthyroidism treated with methimazole, in the proportion of fetuses with suppressed thyroid function. This was contrary to the investigators' expectations, since, “because of its reported limited placental transfer, propylthiouracil is widely preferred over methimazole.” One might be tempted to conclude that.
UR - http://www.scopus.com/inward/record.url?scp=0022883580&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022883580&partnerID=8YFLogxK
U2 - 10.1056/NEJM198612043152312
DO - 10.1056/NEJM198612043152312
M3 - Letter
C2 - 3785300
AN - SCOPUS:0022883580
SN - 0028-4793
VL - 315
SP - 1485
EP - 1486
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 23
ER -